Rozanne C. de Veer

8.0k total citations · 2 hit papers
37 papers, 3.8k citations indexed

About

Rozanne C. de Veer is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Rozanne C. de Veer has authored 37 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hepatology, 29 papers in Epidemiology and 7 papers in Surgery. Recurrent topics in Rozanne C. de Veer's work include Liver Disease Diagnosis and Treatment (29 papers), Hepatitis C virus research (21 papers) and Liver Disease and Transplantation (14 papers). Rozanne C. de Veer is often cited by papers focused on Liver Disease Diagnosis and Treatment (29 papers), Hepatitis C virus research (21 papers) and Liver Disease and Transplantation (14 papers). Rozanne C. de Veer collaborates with scholars based in Netherlands, Canada and Germany. Rozanne C. de Veer's co-authors include Harry L.A. Janssen, M. Rodríguez‐Torres, Hendrik W. Reesink, Michael R. Hodges, Eric Lawitz, Stefan Zeuzem, Bettina E. Hansen, Amy K. Patick, Arthur A. Levin and Yi Zhou and has published in prestigious journals such as New England Journal of Medicine, JAMA and PLoS ONE.

In The Last Decade

Rozanne C. de Veer

35 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of HCV Infection by Targeting MicroRNA

2013 1.7k citations Harry L.A. Janssen, Hendrik W. Reesink et al. New England Journal of Medicine profile →
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

2012 1.1k citations Rozanne C. de Veer, Bart J. Veldt et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rozanne C. de Veer Netherlands	16	2.0k	1.9k	1.4k	1.3k	251	37	3.8k
David Booth Australia	21	1.8k 0.9×	1.5k 0.8×	708 0.5×	58 0.0×	141 0.6×	35	2.9k
Adrian Cotterell United States	26	1.0k 0.5×	665 0.3×	333 0.2×	123 0.1×	1.5k 6.0×	70	2.5k
Kohsaku Sakaguchi Japan	27	1.3k 0.7×	1.1k 0.6×	340 0.3×	148 0.1×	697 2.8×	92	2.5k
Alberto Sánchez‐Fueyo United Kingdom	42	1.9k 0.9×	1.4k 0.8×	856 0.6×	273 0.2×	2.1k 8.2×	118	6.4k
Riccardo Volpes Italy	30	1.9k 0.9×	1.5k 0.8×	236 0.2×	68 0.1×	808 3.2×	90	2.8k
H. Lobeck Germany	28	1.7k 0.8×	1.3k 0.7×	466 0.3×	129 0.1×	1.4k 5.5×	146	3.7k
Victoria Marcus Canada	26	329 0.2×	600 0.3×	521 0.4×	411 0.3×	649 2.6×	72	2.2k
Jean‐Alexis Grimaud France	24	548 0.3×	483 0.3×	462 0.3×	231 0.2×	376 1.5×	45	1.9k
Tsung‐Teh Wu United States	30	631 0.3×	1.2k 0.6×	404 0.3×	184 0.1×	1.5k 6.1×	88	3.3k
Masaaki Kondo Japan	24	733 0.4×	487 0.3×	328 0.2×	140 0.1×	434 1.7×	91	1.6k

Countries citing papers authored by Rozanne C. de Veer

Since Specialization

Citations

This map shows the geographic impact of Rozanne C. de Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rozanne C. de Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rozanne C. de Veer more than expected).

Fields of papers citing papers by Rozanne C. de Veer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rozanne C. de Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rozanne C. de Veer. The network helps show where Rozanne C. de Veer may publish in the future.

Co-authorship network of co-authors of Rozanne C. de Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Rozanne C. de Veer. A scholar is included among the top collaborators of Rozanne C. de Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rozanne C. de Veer. Rozanne C. de Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spaan, Michelle, Nicole S. Erler, Sarwa Darwish Murad, et al.. (2025). Diabetes Mellitus is a Risk Factor for Hepatic Encephalopathy Following Transjugular Intrahepatic Portosystemic Shunt. Alimentary Pharmacology & Therapeutics. 63(7). 967–978. 1 indexed citations

Sonneveld, Milan J., Jeroen de Jonge, Morteza Salarzaei, et al.. (2024). Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation—A European Registry Study. Clinical Transplantation. 38(8). e15437–e15437.

Barten, Thijs R.M., Femke Atsma, Rozanne C. de Veer, et al.. (2023). Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy. Hepatology. 79(3). 551–559.

Maan, Raoel, Amy Puenpatom, Nicole S. Erler, et al.. (2023). Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease. BMJ Open Gastroenterology. 10(1). e001209–e001209. 1 indexed citations

Veer, Rozanne C. de, et al.. (2023). Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment. Frontiers in Medicine. 10. 1195747–1195747. 2 indexed citations

Veldhuijzen, Irene, Maria Prins, Milan J. Sonneveld, et al.. (2023). Substantial impact of the COVID-19 pandemic on the reported number of diagnosed chronic hepatitis C virus infections in the Netherlands, 2019–2021. BMC Public Health. 23(1). 1244–1244. 1 indexed citations

Biewenga, Maaike, Sebastiaan Heidt, Rob A. de Man, et al.. (2022). B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Reports. 4(5). 100460–100460. 8 indexed citations

Mol, Bregje, Jorn Goet, Sanne N. van Munster, et al.. (2022). Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study. Liver International. 43(3). 639–648. 11 indexed citations

Veer, Rozanne C. de, et al.. (2020). Diagnosis and treatment of primary biliary cholangitis. United European Gastroenterology Journal. 8(6). 667–674. 19 indexed citations

10.

Maan, Raoel, Alnoor Ramji, Michael P. Manns, et al.. (2020). Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. Journal of Hepatology. 74(5). 1053–1063. 81 indexed citations

11.

Goet, Jorn, Annarosa Floreani, Xavier Verhelst, et al.. (2019). Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. Journal of Hepatology. 71(5). 992–999. 27 indexed citations

12.

Wong, William, Beate Sander, Chaim M. Bell, et al.. (2018). Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clinical Gastroenterology and Hepatology. 17(9). 1840–1849.e16. 76 indexed citations

13.

Maan, Raoel, et al.. (2017). Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Practice & Research Clinical Gastroenterology. 31(2). 219–225. 3 indexed citations

14.

Veer, Rozanne C. de & Marina Berenguer. (2016). Reversion of disease manifestations after HCV eradication. Journal of Hepatology. 65(1). S95–S108. 131 indexed citations

15.

Maan, Raoel, Rozanne C. de Veer, Willem Pieter Brouwer, et al.. (2015). ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. PLoS ONE. 10(10). e0139317–e0139317. 12 indexed citations

16.

Veer, Rozanne C. de. (2015). Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease?. Expert Review of Gastroenterology & Hepatology. 9(5). 559–566. 13 indexed citations

17.

Ree, Meike H. van der, Rozanne C. de Veer, Joep de Bruijne, et al.. (2014). Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Research. 111. 53–59. 145 indexed citations

18.

Veer, Rozanne C. de, Milan J. Sonneveld, Jeoffrey Schouten, & Harry L.A. Janssen. (2014). [Reversibility of hepatic fibrosis].. PubMed. 158. A6790–A6790. 6 indexed citations

19.

Veer, Rozanne C. de, Heiner Wedemeyer, Jordan J. Feld, et al.. (2014). Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. JAMA. 312(18). 1927–1927. 67 indexed citations

20.

Janssen, Harry L.A., Hendrik W. Reesink, Eric Lawitz, et al.. (2013). Treatment of HCV Infection by Targeting MicroRNA. New England Journal of Medicine. 368(18). 1685–1694. 1683 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact